{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T07:10:38Z","timestamp":1761030638332,"version":"build-2065373602"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008061","name":"Mutua Madrile\u00f1a Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013851","name":"The Pablove Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013851","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Pediatric Neurology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.spen.2021.100873","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T21:11:37Z","timestamp":1612991497000},"page":"100873","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Antibody-Mediated Encephalitis in Children: Focus on Diagnostic Clues and Acute Symptom Management"],"prefix":"10.1016","volume":"37","author":[{"given":"Melissa L.","family":"Hutchinson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anusha K.","family":"Yeshokumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tha\u00eds","family":"Armangue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.spen.2021.100873_bib0001","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ana.25131","article-title":"Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis","volume":"83","author":"Dubey","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1016\/j.spen.2021.100873_bib0002","doi-asserted-by":"crossref","first-page":"e682","DOI":"10.1212\/NXI.0000000000000682","article-title":"Pediatric autoimmune encephalitis: Recognition and diagnosis","volume":"7","author":"de Bruijn","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.spen.2021.100873_bib0003","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/cid\/cir1038","article-title":"The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project","volume":"54","author":"Gable","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.spen.2021.100873_bib0004","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-2543","article-title":"Infectious and autoimmune causes of encephalitis in children","volume":"145","author":"Erickson","year":"2020","journal-title":"Pediatrics"},{"key":"10.1016\/j.spen.2021.100873_bib0005","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ejpn.2019.03.007","article-title":"Pediatric autoimmune encephalitis in Denmark during 2011-17: A nationwide multicenter population-based cohort study","volume":"23","author":"Boesen","year":"2019","journal-title":"Eur J Pediatr Neurol"},{"key":"10.1016\/j.spen.2021.100873_bib0006","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1136\/archdischild-2014-306795","article-title":"N-methyl-D-aspartate receptor antibody-mediated neurological disease: Results of a UK-based surveillance study in children","volume":"100","author":"Wright","year":"2015","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.spen.2021.100873_bib0007","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.braindev.2018.02.005","article-title":"Anti-N-methyl-d-aspartate receptor encephalitis in children: Incidence and experience in Hong Kong","volume":"40","author":"Ho","year":"2018","journal-title":"Brain & Dev"},{"key":"10.1016\/j.spen.2021.100873_bib0008","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1474-4422(19)30488-0","article-title":"Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: A multicentre observational study","volume":"19","author":"Armangue","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.spen.2021.100873_bib0009","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/ana.21756","article-title":"Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents","volume":"66","author":"Florance","year":"2009","journal-title":"Annals Neurol"},{"key":"10.1016\/j.spen.2021.100873_bib0010","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S1474-4422(18)30244-8","article-title":"Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: A prospective observational study and retrospective analysis","volume":"17","author":"Armangue","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.spen.2021.100873_bib0011","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.braindev.2019.09.003","article-title":"Japanese encephalitis-induced anti-N-methyl-d-aspartate receptor encephalitis: A hospital-based prospective study","volume":"42","author":"Ma","year":"2020","journal-title":"Brain & Dev"},{"key":"10.1016\/j.spen.2021.100873_bib0012","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: An observational cohort study","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.spen.2021.100873_bib0013","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1212\/WNL.0b013e3182698cd8","article-title":"Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis","volume":"79","author":"Schmitt","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2021.100873_bib0014","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.yebeh.2017.09.022","article-title":"Electroencephalographic findings in anti-N-methyl-d-aspartate receptor encephalitis in children: A series of 12 patients","volume":"78","author":"Yildirim","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.spen.2021.100873_bib0015","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1474-4422(13)70282-5","article-title":"Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: A retrospective study","volume":"13","author":"Gresa-Arribas","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.spen.2021.100873_bib0016","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12974-016-0717-1","article-title":"MOG-IgG in NMO and related disorders: A multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflamm"},{"key":"10.1016\/j.spen.2021.100873_bib0017","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: International recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J Neuroinflamm"},{"key":"10.1016\/j.spen.2021.100873_bib0018","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.spen.2021.100873_bib0019","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/dmcn.13579","article-title":"High sensitivity and specificity in proposed clinical diagnostic criteria for anti-N-methyl-D-aspartate receptor encephalitis","volume":"59","author":"Ho","year":"2017","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.spen.2021.100873_bib0020","doi-asserted-by":"crossref","first-page":"e663","DOI":"10.1212\/NXI.0000000000000663","article-title":"Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient","volume":"7","author":"Cellucci","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.spen.2021.100873_bib0021","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/WCO.0000000000000443","article-title":"Autoimmune encephalitis in children: Clinical phenomenology, therapeutics, and emerging challenges","volume":"30","author":"Dale","year":"2017","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.spen.2021.100873_bib0022","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s10072-019-03930-3","article-title":"Management of antibody-mediated autoimmune encephalitis in adults and children: Literature review and consensus-based practical recommendations","volume":"40","author":"Zuliani","year":"2019","journal-title":"Neuro Sci"},{"key":"10.1016\/j.spen.2021.100873_bib0023","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.pedneo.2018.10.006","article-title":"Immunotherapy for anti-NMDA receptor encephalitis: Experience from a single center in Taiwan","volume":"60","author":"Kong","year":"2019","journal-title":"Pediatr Neonatol"},{"key":"10.1016\/j.spen.2021.100873_bib0024","doi-asserted-by":"crossref","first-page":"596","DOI":"10.3389\/fneur.2019.00596","article-title":"Clinical features, treatment, and outcomes among Chinese children with anti-methyl-D-aspartate receptor (Anti-NMDAR)","volume":"10","author":"Zhang","year":"2019","journal-title":"Encephalitis. Front Neurol."},{"key":"10.1016\/j.spen.2021.100873_bib0025","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.spen.2021.100873_bib0026","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","article-title":"Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"75","author":"Hacohen","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.spen.2021.100873_bib0027","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1212\/WNL.0000000000000570","article-title":"Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease","volume":"83","author":"Dale","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2021.100873_bib0028","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1212\/NXI.0000000000000724","article-title":"Single-cycle rituximab-induced immunologic changes in children: Enhanced in neuroimmunologic disease?","volume":"7","author":"Deya-Martinez","year":"2020","journal-title":"Neuro Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.spen.2021.100873_bib0029","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s13311-016-0442-6","article-title":"Tocilizumab in autoimmune encephalitis refractory to rituximab: An institutional cohort study","volume":"13","author":"Lee","year":"2016","journal-title":"Neurother"},{"key":"10.1016\/j.spen.2021.100873_bib0030","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/ene.13759","article-title":"Plasma cell depletion with bortezomib in the treatment of refractory N-methyl-d-aspartate (NMDA) receptor antibody encephalitis. Rational developments in neuroimmunological treatment","volume":"25","author":"Keddie","year":"2018","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.spen.2021.100873_bib0031","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3389\/fneur.2020.00188","article-title":"Early bortezomib therapy for refractory anti-NMDA receptor encephalitis","volume":"11","author":"Turnbull","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.spen.2021.100873_bib0032","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/dmcn.12882","article-title":"Symptomatic treatment of children with anti-NMDAR encephalitis","volume":"58","author":"Mohammad","year":"2016","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.spen.2021.100873_bib0033","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.pediatrneurol.2019.11.011","article-title":"Seizure characteristics, outcome, and risk of epilepsy in pediatric anti-N-methyl-d-aspartate receptor encephalitis","volume":"105","author":"Qu","year":"2020","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.spen.2021.100873_bib0034","doi-asserted-by":"crossref","first-page":"e2185","DOI":"10.1212\/WNL.0000000000007475","article-title":"Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis","volume":"92","author":"de Bruijn","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2021.100873_bib0035","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1089\/cap.2016.0102","article-title":"Agitation management in pediatric males with anti-N-methyl-D-aspartate receptor encephalitis","volume":"26","author":"Schumacher","year":"2016","journal-title":"J Child & Adolesc Psychopharmacol"},{"key":"10.1016\/j.spen.2021.100873_bib0036","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/WCO.0000000000000449","article-title":"Seizures and risk of epilepsy in autoimmune and other inflammatory encephalitis","volume":"30","author":"Spatola","year":"2017","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.spen.2021.100873_bib0037","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jocn.2018.10.076","article-title":"Proportion and spectrum of movement disorders in adolescent and adult patients of autoimmune encephalitis of non-neoplastic aetiology","volume":"59","author":"Dash","year":"2019","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.spen.2021.100873_bib0038","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/mds.25354","article-title":"The spectrum of movement disorders in children with anti-NMDA receptor encephalitis","volume":"28","author":"Baizabal-Carvallo","year":"2013","journal-title":"Mov Disord"},{"key":"10.1016\/j.spen.2021.100873_bib0039","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3389\/fneur.2018.00081","article-title":"Management of refractory orofacial dyskinesia caused by anti-N-methyl-d-aspartate receptor encephalitis using botulinum toxin","volume":"9","author":"Zheng","year":"2018","journal-title":"Front Neurol"},{"key":"10.1016\/j.spen.2021.100873_bib0040","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s12028-019-00875-5","article-title":"Treatment of movement disorder emergencies in autoimmune encephalitis in the neurosciences ICU","volume":"32","author":"Ali","year":"2020","journal-title":"Neurocrit Care"},{"key":"10.1016\/j.spen.2021.100873_bib0041","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.brs.2018.11.016","article-title":"Electroconvulsive therapy for anti-N-methyl-d-aspartate (NMDA) receptor encephalitis: A systematic review of cases","volume":"12","author":"Warren","year":"2019","journal-title":"Brain Stimul"},{"key":"10.1016\/j.spen.2021.100873_bib0042","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.chc.2017.08.011","article-title":"Evaluation and management of autoimmune encephalitis: a clinical overview for the practicing child psychiatrist","volume":"27","author":"Mooneyham","year":"2018","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"key":"10.1016\/j.spen.2021.100873_bib0043","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/acn3.467","article-title":"Botulinum toxin treatment for hypersalivation in anti-NMDA receptor encephalitis","volume":"4","author":"Jun","year":"2017","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.spen.2021.100873_bib0044","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jneuroim.2017.08.010","article-title":"Neurobehavioral outcomes in autoimmune encephalitis","volume":"312","author":"Yeshokumar","year":"2017","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.spen.2021.100873_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107088","article-title":"Assessment of long-term psychosocial outcomes in anti-NMDA receptor encephalitis","volume":"108","author":"Blum","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.spen.2021.100873_bib0046","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/jnnp-2011-300411","article-title":"Cognitive deficits following anti-NMDA receptor encephalitis","volume":"83","author":"Finke","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.spen.2021.100873_bib0047","doi-asserted-by":"crossref","first-page":"e1997","DOI":"10.1212\/WNL.0000000000005605","article-title":"Long-term neuropsychological outcome following pediatric anti-NMDAR encephalitis","volume":"90","author":"de Bruijn","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2021.100873_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107066","article-title":"Assessment of care transitions and caregiver burden in anti-NMDA receptor encephalitis","volume":"108","author":"Tomlinson","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.spen.2021.100873_bib0049","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-224169","article-title":"Neuropsychological assessment as an objective tool to monitor treatment response in anti-N-methyl-D-aspartate receptor encephalitis","volume":"2018","author":"Sieg","year":"2018","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.spen.2021.100873_bib0050","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1212\/WNL.0000000000003713","article-title":"Investigations in GABAA receptor antibody-associated encephalitis","volume":"88","author":"Spatola","year":"2017","journal-title":"Neurology."},{"key":"10.1016\/j.spen.2021.100873_bib0051","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S1474-4422(13)70299-0","article-title":"Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: A case series, characterisation of the antigen, and analysis of the effects of antibodies","volume":"13","author":"Petit-Pedrol","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.spen.2021.100873_bib0052","doi-asserted-by":"crossref","first-page":"e1964","DOI":"10.1212\/WNL.0000000000005614","article-title":"Encephalitis with mGluR5 antibodies: Symptoms and antibody effects","volume":"90","author":"Spatola","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2021.100873_bib0053","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1212\/WNL.0b013e3182364a44","article-title":"Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome","volume":"77","author":"Lancaster","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2021.100873_bib0054","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1093\/brain\/aws256","article-title":"Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders","volume":"135","author":"Dale","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.spen.2021.100873_bib0055","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/mds.25999","article-title":"Movement disorders in children with anti-NMDAR encephalitis and other autoimmune encephalopathies","volume":"29","author":"Mohammad","year":"2014","journal-title":"Mov Disord"}],"container-title":["Seminars in Pediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071909121000012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071909121000012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T06:38:11Z","timestamp":1761028691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071909121000012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":55,"alternative-id":["S1071909121000012"],"URL":"https:\/\/doi.org\/10.1016\/j.spen.2021.100873","relation":{},"ISSN":["1071-9091"],"issn-type":[{"type":"print","value":"1071-9091"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody-Mediated Encephalitis in Children: Focus on Diagnostic Clues and Acute Symptom Management","name":"articletitle","label":"Article Title"},{"value":"Seminars in Pediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.spen.2021.100873","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100873"}}